A light-and-sound headset may slow Alzheimer's. Canada's access system, built for molecules, has nowhere to put it.
The 40 Hz idea is real science, contested in the places that matter, with a pivotal trial due mid-2026. The harder question is the one no one else is asking: if it works, Canada's drug-built access pipeline has nowhere to put a device — and no way to pay for it.
The 40 Hz light-and-sound approach to Alzheimer's (GENUS, from MIT's Tsai lab) is carried toward market by Cognito Therapeutics' Spectris AD headset, whose pivotal HOPE trial (NCT05637801, 670 participants) reads out topline in mid-2026. The device holds FDA Breakthrough Device Designation but is authorized nowhere, and the animal evidence is contested by replication failures. Canada's reimbursement pathway — Health Canada → CADTH/INESSS → pCPA → formulary — is built for drugs, not devices.
Every few months a thread goes around claiming that flickering lights and pulsing tones at 40 hertz can clear the plaques behind Alzheimer's disease. It is a genuinely seductive idea — non-invasive, drug-free, home-based, the brain healing itself if you only show it the right rhythm — and it is built on real science from a serious lab. It is also, in the telling that travels, missing the half of the story that determines whether any Canadian patient will ever benefit: the replication fights inside the evidence base, and the reimbursement void waiting on the other side of approval. The first is a question for neuroscientists. The second is the one this publication exists to ask, and almost nobody is asking it.
Create a free account to read the full interpretation.
You’ve reached the part where The Indication earns its name — the read on distribution, reimbursement timing, and channel strategy. It’s free to finish: sign in or create an account to keep reading every analysis in full.